Feng Chen, PhD

Medical School Department Internal Medicine
Research Program Mechanisms of Cancer Biology Program
Feng Chen

Researcher Background

Primary Academic Title

Professor of Medicine, WashU Medicine

Training

  • 1998 - 2002: Fellow, Molecular Genetics, Stanford University, Palo Alto, CA

Education

  • 1998: PhD, Human Genetics, University of Utah School of Medicine, Salt Lake City, UT

Research & Selected Publications

Research Interest

The genetic determinants and pathogenic mechanisms of benign and malignant urogenital diseases with the goal of improving diagnostic and therapeutic strategies targeting these diseases. Creating and utilizing an array of experimental and disease models in mice to study the involvement of calcineurin-NFAT and other pathways in CAKUT (Congenital Anomalies of the Kidney and the Urinary tract), glomerular diseases, and urogenital cancers.

Research Publications

Multi-omic and spatial analysis of mouse kidneys highlights sex-specific differences in gene regulation across the lifespan.
Authors:

Chen S, Liu R, Mo CK, one or more additional authors omitted Chen F

Journal & Year:

Nat Genet • 2025

SenNet recommendations for detecting senescent cells in different tissues.
Authors:

Suryadevara V, Hudgins AD, Rajesh A, one or more additional authors omitted Chen F, one or more additional authors omitted Neretti N

Journal & Year:

Nat Rev Mol Cell Biol • 2024

Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages.
Authors:

Iglesia MD, Jayasinghe RG, Chen S, one or more additional authors omitted Chen F, one or more additional authors omitted Ding L

Journal & Year:

Nat Cancer • 2024

Tumour evolution and microenvironment interactions in 2D and 3D space.
Authors:

Mo CK, Liu J, Chen S, one or more additional authors omitted Chen F, Ding L

Journal & Year:

Nature • 2024

Multi-scale signaling and tumor evolution in high-grade gliomas.
Authors:

Liu J, Cao S, Imbach KJ, one or more additional authors omitted Chen F, one or more additional authors omitted Ding L

Journal & Year:

Cancer Cell • 2024

Comprehensive proteogenomic characterization of rare kidney tumors.
Authors:

Li GX, Chen L, Hsiao Y, one or more additional authors omitted Chen F, one or more additional authors omitted Nesvizhskii AI

Journal & Year:

Cell Rep Med • 2024

Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma.
Authors:

Wu Y, Chen S, Yang X, one or more additional authors omitted Chen F

Journal & Year:

Cancer Res • 2023

Epigenetic regulation during cancer transitions across 11 tumour types.
Authors:

Terekhanova NV, Karpova A, Liang WW, one or more additional authors omitted Chen F, one or more additional authors omitted Ding L

Journal & Year:

Nature • 2023